Biotech Values

[mcbio]

If they want to succeed, they shouldn't. They rushed original Viaject formula to phase 3. Even if it were approved, it would be commercial bust due to discomfort at injection site.

Phase 1 and 2 insulin program doesn't take that long, You can finish both in a little bit over one year. Look at HALO. One of key reasons why many small biotech have lower phase 3 success rate is they rush, don't think through by taking too many chances. The odds aren't with you in the casino.

I hear you on all those points but, at the same time, time isn't exactly on BIOD's side given that they have just a little over a year left of cash and can't assume they'll be in a position to raise cash on favorable terms given the valuation. Absent a partnership, they may have to take the boom or bust path forward of moving straight into Phase 3.